Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell…
Consensus price target: $1,120.00 (+41228.41% upside from $2.71)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $36.31M | +4.11% | $-5.98M |
| 2024 | $34.87M | +44.75% | $-5.13M |
| 2023 | $24.09M | +454.42% | $-4.51M |
Stock data for SBFM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics